Q-omics provides the consensus-scored PHBP9 profile across patient tissues and cancer cell-line models. PHBP9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, PHBP9 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PHBP9 RNA expression shows 19,624 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, COAD, and THYM as cancer lineages where PHBP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHBP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHBP9 survival associations across molecular data types. PHBP9 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHBP9 RNA expression–survival associations across cancer types. High PHBP9 expression shows unfavorable associations in THCA, KIRC, COAD and ACC, but favorable associations in SKCM and UCS. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for PHBP9 RNA expression.
This table summarizes PHBP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PHBP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHBP9 shows lower tumor expression in BRCA and KICH and higher tumor expression in COAD, HNSC, CHOL and LIHC. The COAD box plot shows higher PHBP9 RNA expression in tumor versus normal tissue (log2 FC = +0.387, t-test p < 0.001).
This table shows molecular features associated with PHBP9 in patient tissues and cancer cell lines. In patient samples, PHBP9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
